This trial is evaluating whether Pirtobrutinib will improve 1 primary outcome and 7 secondary outcomes in patients with Chronic Lymphocytic Leukemia (CLL). Measurement will happen over the course of Up to approximately 5 years.
This trial requires 250 total participants across 2 different treatment groups
This trial involves 2 different treatments. Pirtobrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Results from a recent clinical trial showed that about 35% of patients who presented to the hospital with lymphoma died within 3 years after diagnosis. This is higher than expected because of the severity of lymphoma. In particular, follicular lymphoma had the highest mortality rate. More than half of deaths associated with lymphoma were caused by complications related to the disease. Results from a recent clinical trial suggest that lymphoma is an important cause of morbidity and mortality in hospitalized patients." - Anonymous Online Contributor
"PBT shows promise as a promising new drug for treating HL, especially in combination with rituximab, and is being considered by multiple investigators as a potentially effective strategy for treating patients with relapsed or refractory HL. Clinical trials examining these combinations and/or in combination with other agents (e.g., belinostat), and studies investigating the impact of these therapies on progression free survival and overall survival are ongoing." - Anonymous Online Contributor
"PBT is effective in reducing disease activity and prolonging PFS in patients with relapsed/refractory rituximab-responsive indolent non-Hodgkin lymphoma harboring biallelic mutations in either the ABCG2 or BCR gene. PBT is well tolerated, with most adverse events being mild or moderate. Most patients will require ongoing immunosuppression. ClinicalTrials.gov identifier: NCT01931042." - Anonymous Online Contributor
"Though there are no cures for lymphomas, there is research underway to find treatments which may improve survival. In particular, TNF alpha inhibitors such as infliximab are being tested against rituximab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Further studies are needed to determine whether these agents work in patients with primary mediastinal B-cell lymphomas." - Anonymous Online Contributor
"The overall 5-year survival rate for all types of lymphoma was 89.9%, 94% with MALT, 93.8% with T-cell lymphoma, 87.8% with follicular lymphoma and 86.7% with small lymphocytic lymphoma. In addition, these rates were 91.4% with B-cell lymphoma, 88.6% with Hodgkin’s disease, 82.5% with diffuse large B-cell lymphoma, 81.6% with Burkitt’s lymphoma and 80% with chronic lymphocytic leukemia. These are comparable to those reported elsewhere. It seems reasonable to assume that survival in lymphoma has improved over the last 40 years." - Anonymous Online Contributor
"Based on the results presented here, it appears that if we provide an accurate definition of lymphoma then people will be more likely to recognize and know about lymphoma. If we are able to correctly identify lymphoma, people will be better able to understand the importance of early detection and treatment." - Anonymous Online Contributor
"It is suggested that a lymphoma screening programme should be established for at risk populations, including those living overseas who are not compliant with routine immunisation programmes." - Anonymous Online Contributor
"PBTNIB demonstrated promising activity in both relapsed or refractory CLL/SLL and MM. However, preliminary data suggest that pirtobrutinib appears to have fewer adverse events and comparable safety profile compared with other IMiDs." - Anonymous Online Contributor
"Recent findings indicate that familial clustering of lymphoma is real in some but not all families. Further research needs to be done to determine if familial clustering is related to genetic or environmental factors." - Anonymous Online Contributor
"PBT is typically used in combination with other treatments. In contrast to other BTs, which have been found to be effective in single-agent regimens, pBT can be considered a standard 2-drug regimen." - Anonymous Online Contributor
"PBT may be associated with improvements in HRQoL among patients with primary or secondary lymphoma compared to mTOR inhibitors alone. Results from a recent paper warrant further investigation of PBT as a first line therapy for this patient population." - Anonymous Online Contributor